Effect of intravenous glucagon infusion on renal haemodynamics and renal tubular handling of sodium in healthy humans.

Schwartz Sørensen S, Eiskjaer H, Orskov H, Bjerregaard Pedersen E

Scandinavian journal of clinical and laboratory investigation1 Feb 1993Cited by 6 (Europe PMC)

PMID8451599DOI10.3109/00365519309092528PepBankPUB-08451599

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialPharmacokinetics
In healthy volunteers, glucagon infusion increased plasma glucagon by a maximum of 400%.
In plain wordsIn healthy volunteers, glucagon infusion increased drug levels above baseline.
Peptide
Glucagon
Outcome
IncreasePlasma glucagon concentration
Study
n = 10
Comparator
Baseline
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
5 ng kg-1 min-1 · intravenous · 2 hAs given in this study (human).
Measurements
Maximal increase in plasma glucagon
400%
Glucagon infusion, 5 ng kg-1 min-1
Source sentences
Summary
Glucagon infusion resulted in a maximal increase in plasma concentrations of glucagon of 400%.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 2-h intravenous infusion of glucagon 5 ng kg-1 min-1 or placebo on glomerular filtration rate (GFR), renal plasma flow (RPF), tubular sodium handling as judged by the lithium clearance method, and plasma concentrations of angiotensin II (AngII), aldosterone (Aldo), and atrial natriuretic factor (ANF)
Summary · context
were investigated in two groups of healthy human volunteers, glucagon group (n = 10), and placebo group (n = 10).
Report a problemFND-0845159901
02HumanNon-randomized trialEfficacy outcome
In healthy volunteers, glucagon increased GFR by 5.9% throughout infusion, range 1.3-12.4, p < 0.001.
In plain wordsIn healthy volunteers, glucagon increased kidney filtration above baseline throughout infusion.
Peptide
Glucagon
Outcome
IncreaseGlomerular filtration rate
Study
n = 10
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
5 ng kg-1 min-1 · intravenous · 2 hAs given in this study (human).
Measurements
GFR increase
5.9%
Glucagon infusion, whole infusion period
GFR increase, range
1.3 to 12.4%
Glucagon infusion
p-value
< 0.001 p
GFR increase
Source sentences
Summary
GFR increased 5.9% (range 1.3-12.4, p < 0.001) through the whole infusion period, whereas RPF only increased transiently during the first hour of infusion 6.5% (range 2.6-15.3, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 2-h intravenous infusion of glucagon 5 ng kg-1 min-1 or placebo on glomerular filtration rate (GFR), renal plasma flow (RPF), tubular sodium handling as judged by the lithium clearance method, and plasma concentrations of angiotensin II (AngII), aldosterone (Aldo), and atrial natriuretic factor (ANF)
Summary · context
were investigated in two groups of healthy human volunteers, glucagon group (n = 10), and placebo group (n = 10).
Report a problemFND-0845159902
03HumanNon-randomized trialEfficacy outcome
In healthy volunteers, glucagon transiently increased renal plasma flow by 6.5% during the first hour, range 2.6-15.3, p < 0.05.
In plain wordsIn healthy volunteers, glucagon briefly increased kidney blood flow above baseline.
Peptide
Glucagon
Outcome
IncreaseRenal plasma flow
Study
n = 10
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
5 ng kg-1 min-1 · intravenous · 2 hAs given in this study (human).
Measurements
RPF increase
6.5%
Glucagon infusion, first hour only
RPF increase, range
2.6 to 15.3%
Glucagon infusion, first hour
p-value
< 0.05 p
RPF increase
Source sentences
Summary
GFR increased 5.9% (range 1.3-12.4, p < 0.001) through the whole infusion period, whereas RPF only increased transiently during the first hour of infusion 6.5% (range 2.6-15.3, p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 2-h intravenous infusion of glucagon 5 ng kg-1 min-1 or placebo on glomerular filtration rate (GFR), renal plasma flow (RPF), tubular sodium handling as judged by the lithium clearance method, and plasma concentrations of angiotensin II (AngII), aldosterone (Aldo), and atrial natriuretic factor (ANF)
Summary · context
were investigated in two groups of healthy human volunteers, glucagon group (n = 10), and placebo group (n = 10).
Report a problemFND-0845159903
04HumanNon-randomized trialEfficacy outcome
In healthy volunteers, glucagon significantly increased filtered sodium load, p < 0.001.
In plain wordsIn healthy volunteers, glucagon increased filtered sodium above baseline.
Peptide
Glucagon
Outcome
IncreaseFiltered sodium load
Study
n = 10
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
5 ng kg-1 min-1 · intravenous · 2 hAs given in this study (human).
Measurements
p-value
< 0.001 p
Filtered sodium load increase
Source sentences
Summary
Whereas filtered load of sodium increased significantly in response to glucagon infusion (p < 0.001), urinary sodium excretion was unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 2-h intravenous infusion of glucagon 5 ng kg-1 min-1 or placebo on glomerular filtration rate (GFR), renal plasma flow (RPF), tubular sodium handling as judged by the lithium clearance method, and plasma concentrations of angiotensin II (AngII), aldosterone (Aldo), and atrial natriuretic factor (ANF)
Summary · context
were investigated in two groups of healthy human volunteers, glucagon group (n = 10), and placebo group (n = 10).
Report a problemFND-0845159904
05HumanNon-randomized trialEfficacy outcome
In healthy volunteers, urinary sodium excretion remained unchanged during glucagon infusion.
In plain wordsIn healthy volunteers, glucagon did not change urinary sodium excretion from baseline.
Peptide
Glucagon
Outcome
No significant changeUrinary sodium excretion
Study
n = 10
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
5 ng kg-1 min-1 · intravenous · 2 hAs given in this study (human).
Source sentences
Summary
Whereas filtered load of sodium increased significantly in response to glucagon infusion (p < 0.001), urinary sodium excretion was unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 2-h intravenous infusion of glucagon 5 ng kg-1 min-1 or placebo on glomerular filtration rate (GFR), renal plasma flow (RPF), tubular sodium handling as judged by the lithium clearance method, and plasma concentrations of angiotensin II (AngII), aldosterone (Aldo), and atrial natriuretic factor (ANF)
Summary · context
were investigated in two groups of healthy human volunteers, glucagon group (n = 10), and placebo group (n = 10).
Report a problemFND-0845159905
06HumanNon-randomized trialEfficacy outcome
In healthy volunteers, glucagon infusion increased sodium output from the proximal tubules by a magnitude similar to the increased filtered load.
In plain wordsIn healthy volunteers, glucagon increased sodium leaving the kidney's proximal tubules above baseline.
Peptide
Glucagon
Outcome
IncreaseProximal tubular sodium output
Study
n = 10
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
5 ng kg-1 min-1 · intravenous · 2 hAs given in this study (human).
Source sentences
Summary
the increased filtered load of sodium resulted in an increase in the output of sodium from the proximal tubules of a similar magnitude,
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 2-h intravenous infusion of glucagon 5 ng kg-1 min-1 or placebo on glomerular filtration rate (GFR), renal plasma flow (RPF), tubular sodium handling as judged by the lithium clearance method, and plasma concentrations of angiotensin II (AngII), aldosterone (Aldo), and atrial natriuretic factor (ANF)
Summary · context
were investigated in two groups of healthy human volunteers, glucagon group (n = 10), and placebo group (n = 10).
Report a problemFND-0845159906
07HumanNon-randomized trialEfficacy outcome
In healthy volunteers, increased distal sodium reabsorption fully counterbalanced the greater distal sodium input during glucagon infusion.
In plain wordsIn healthy volunteers, distal kidney tubules reabsorbed more sodium than at baseline during glucagon infusion.
Peptide
Glucagon
Outcome
IncreaseDistal tubular sodium reabsorption
Study
n = 10
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
5 ng kg-1 min-1 · intravenous · 2 hAs given in this study (human).
Source sentences
Summary
and an increase in absolute reabsorption of sodium in the distal tubules totally counterbalancing this increased input to the distal tubules.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 2-h intravenous infusion of glucagon 5 ng kg-1 min-1 or placebo on glomerular filtration rate (GFR), renal plasma flow (RPF), tubular sodium handling as judged by the lithium clearance method, and plasma concentrations of angiotensin II (AngII), aldosterone (Aldo), and atrial natriuretic factor (ANF)
Summary · context
were investigated in two groups of healthy human volunteers, glucagon group (n = 10), and placebo group (n = 10).
Report a problemFND-0845159907
08HumanNon-randomized trialMechanism
In healthy volunteers, glucagon-related tubular sodium changes did not involve angiotensin II, aldosterone, or atrial natriuretic factor.
In plain wordsIn healthy volunteers, the reported kidney changes during glucagon infusion did not involve the three specified hormones.
Peptide
Glucagon
Outcome
Not applicableHormonal involvement in tubular sodium changes
Study
n = 10
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
5 ng kg-1 min-1 · intravenous · 2 hAs given in this study (human).
Source sentences
Summary
These alterations in tubular sodium handling did not involve Ang II, Aldo, or ANF.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of a 2-h intravenous infusion of glucagon 5 ng kg-1 min-1 or placebo on glomerular filtration rate (GFR), renal plasma flow (RPF), tubular sodium handling as judged by the lithium clearance method, and plasma concentrations of angiotensin II (AngII), aldosterone (Aldo), and atrial natriuretic factor (ANF)
Summary · context
were investigated in two groups of healthy human volunteers, glucagon group (n = 10), and placebo group (n = 10).
Report a problemFND-0845159908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.